HIV-1 replication in monocyte-derived dendritic cells is stimulated by melarsoprol, one of the main drugs against human african trypanosomiasis

Journal of Molecular Biology

Volumn 410, Issue 5, 2011, Pages 1052-1064

  Barat, Corinne ^a   Pepin, Jacques ^b   Tremblay, Michel J ^a  

^a UNIVERSITÉ LAVAL   (Canada)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

Author keywords

AIDS; APOBEC3G; arsenic; co infection; sleeping sickness

Indexed keywords

ALPHA INTERFERON; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; ARSENIC TRIOXIDE; CD19 ANTIGEN; CD3 ANTIGEN; MELARSOPROL; TRYPARSAMIDE;

AFRICAN TRYPANOSOMIASIS; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL STRAIN HEK293; DENDRITIC CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2; INFECTION SENSITIVITY; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS GENE; VIRUS REPLICATION; VIRUS TRANSMISSION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; PROTOZOA; TRYPANOSOMA BRUCEI;

EID: 79960363446     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2011.03.012     Document Type: Article

References (48)

1. Kennedy P.G. The continuing problem of human African trypanosomiasis (sleeping sickness) Ann. Neurol. 64 2008 116 126
2. Simarro P.P.; Jannin J.; and Cattand P. Eliminating human African trypanosomiasis: where do we stand and what comes next? PLoS Med. 5 2008 e55
3. Pepin J.; Ethier L.; Kazadi C.; Milord F.; and Ryder R. The impact of human immunodeficiency virus infection on the epidemiology and treatment of Trypanosoma brucei gambiense sleeping sickness in Nioki Zaire. Am. J. Trop. Med. Hyg. 47 1992 133 140
4. Blum J.; Nkunku S.; and Burri C. Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis Trop. Med. Int. Health 6 2001 390 400 (Pubitemid 32510076)
5. Fairlamb A.H. Chemotherapy of human African trypanosomiasis: current and future prospects Trends Parasitol. 19 2003 488 494 (Pubitemid 37329657)
6. Brun R.; Blum J.; Chappuis F.; and Burri C. Human African trypanosomiasis Lancet 375 2010 148 159
7. Priotto G.; Kasparian S.; Mutombo W.; Ngouama D.; Ghorashian S.; and Arnold U. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial Lancet 374 2009 56 64
8. Pepin J.; and Milord F. The treatment of human African trypanosomiasis Adv. Parasitol. 33 1994 1 47 (Pubitemid 23357084)
9. Nok A.J. Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis Parasitol Res. 90 2003 71 79 (Pubitemid 36577873)
10. Berthoux L.; Towers G.J.; Gurer C.; Salomoni P.; Pandolfi P.P.; and Luban J. As(2)O(3) enhances retroviral reverse transcription and counteracts Ref1 antiviral activity J. Virol. 77 2003 3167 3180 (Pubitemid 36228101)
11. Sebastian S.; Sokolskaja E.; and Luban J. Arsenic counteracts human immunodeficiency virus type 1 restriction by various TRIM5 orthologues in a cell type-dependent manner J. Virol. 80 2006 2051 2054 (Pubitemid 43228745)
12. Turelli P.; Doucas V.; Craig E.; Mangeat B.; Klages N.; and Evans R. Cytoplasmic recruitment of INI1 and PML on incoming HIV preintegration complexes: interference with early steps of viral replication Mol. Cell 7 2001 1245 1254 (Pubitemid 32607358)
13. Pion M.; Stalder R.; Correa R.; Mangeat B.; Towers G.J.; and Piguet V. Identification of an arsenic-sensitive block to primate lentiviral infection of human dendritic cells J. Virol. 81 2007 12086 12090 (Pubitemid 47623841)
14. Barat C.; Zhao C.; Ouellette M.; and Tremblay M.J. HIV-1 replication is stimulated by sodium stibogluconate, the therapeutic mainstay in the treatment of leishmaniasis J. Infect. Dis. 195 2007 236 245 (Pubitemid 46080056)
15. Bakri Y.; Schiffer C.; Zennou V.; Charneau P.; Kahn E.; and Benjouad A. The maturation of dendritic cells results in postintegration inhibition of HIV-1 replication J. Immunol. 166 2001 3780 3788 (Pubitemid 32224902)
16. Cavrois M.; Neidleman J.; Kreisberg J.F.; Fenard D.; Callebaut C.; and Greene W.C. Human immunodeficiency virus fusion to dendritic cells declines as cells mature J. Virol. 80 2006 1992 1999 (Pubitemid 43228739)
17. Pion M.; Arrighi J.F.; Jiang J.; Lundquist C.A.; Hartley O.; Aiken C.; and Piguet V. Analysis of HIV-1-X4 fusion with immature dendritic cells identifies a specific restriction that is independent of CXCR4 levels J. Invest. Dermatol. 127 2007 319 323 (Pubitemid 46106909)
18. Cavrois M.; De Noronha C.; and Greene W.C. A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes Nat. Biotechnol. 20 2002 1151 1154 (Pubitemid 35285446)
19. Pion M.; Granelli-Piperno A.; Mangeat B.; Stalder R.; Correa R.; Steinman R.M.; and Piguet V. APOBEC3G/3F mediates intrinsic resistance of monocyte-derived dendritic cells to HIV-1 infection J. Exp. Med. 203 2006 2887 2893 (Pubitemid 46026166)
20. Trapp S.; Derby N.R.; Singer R.; Shaw A.; Williams V.G.; and Turville S.G. Double-stranded RNA analog poly(I:C) inhibits human immunodeficiency virus amplification in dendritic cells via type I interferon-mediated activation of APOBEC3G J. Virol. 83 2009 884 895
21. Anderson J.L.; Campbell E.M.; Wu X.; Vandegraaff N.; Engelman A.; and Hope T.J. Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins J. Virol. 80 2006 9754 9760 (Pubitemid 44435649)
22. Schwartz O.; Marechal V.; Friguet B.; Arenzana-Seisdedos F.; and Heard J.M. Antiviral activity of the proteasome on incoming human immunodeficiency virus type 1 J. Virol. 72 1998 3845 3850 (Pubitemid 28188684)
23. Bishop K.N.; Verma M.; Kim E.Y.; Wolinsky S.M.; and Malim M.H. APOBEC3G inhibits elongation of HIV-1 reverse transcripts PLoS Pathog. 4 2008 e1000231
24. Okeoma C.M.; Low A.; Bailis W.; Fan H.Y.; Peterlin B.M.; and Ross S.R. Induction of APOBEC3 in vivo causes increased restriction of retrovirus infection J. Virol. 83 2009 3486 3495
25. Peng G.; Greenwell-Wild T.; Nares S.; Jin W.; Lei K.J.; and Rangel Z.G. Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression Blood 110 2007 393 400 (Pubitemid 47026861)
26. Koning F.A.; Newman E.N.; Kim E.Y.; Kunstman K.J.; Wolinsky S.M.; and Malim M.H. Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets J. Virol. 83 2009 9474 9485
27. Ogawa Y.; Kawamura T.; Kimura T.; Ito M.; Blauvelt A.; and Shimada S. Gram-positive bacteria enhance HIV-1 susceptibility in Langerhans cells, but not in dendritic cells, via Toll-like receptor activation Blood 113 2009 5157 5166
28. Peng G.; Lei K.J.; Jin W.; Greenwell-Wild T.; and Wahl S.M. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity J. Exp. Med. 203 2006 41 46
29. Wang F.X.; Huang J.; Zhang H.; Ma X.; and Zhang H. APOBEC3G upregulation by alpha interferon restricts human immunodeficiency virus type 1 infection in human peripheral plasmacytoid dendritic cells J. Gen. Virol. 89 2008 722 730
30. Stalder R.; Blanchet F.; Mangeat B.; and Piguet V. Arsenic modulates APOBEC3G-mediated restriction to HIV-1 infection in myeloid dendritic cells J. Leukoc. Biol. 88 2010 1251 1258
31. Rousselot P.; Labaume S.; Marolleau J.P.; Larghero J.; Noguera M.H.; Brouet J.C.; and Fermand J.P. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients Cancer Res. 59 1999 1041 1048 (Pubitemid 29135964)
32. Sumi D.; Shinkai Y.; and Kumagai Y. Signal transduction pathways and transcription factors triggered by arsenic trioxide in leukemia cells Toxicol. Appl. Pharmacol. 244 2010 385 392
33. Antoine F.; Ennaciri J.; and Girard D. Syk is a novel target of arsenic trioxide (ATO) and is involved in the toxic effect of ATO in human neutrophils Toxicol. in Vitro 24 2010 936 941
34. Binet F.; Antoine F.; and Girard D. Interaction between arsenic trioxide and human primary cells: emphasis on human cells of myeloid origin Inflamm. Allergy Drug Targets 8 2009 21 27
35. Burri C.; Baltz T.; Giroud C.; Doua F.; Welker H.A.; and Brun R. Pharmacokinetic properties of the trypanocidal drug melarsoprol Chemotherapy 39 1993 225 234 (Pubitemid 23198849)
36. Burri C.; and Keiser J. Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment Trop. Med. Int. Health 6 2001 412 420 (Pubitemid 32510079)
37. Lemey P.; Pybus O.G.; Wang B.; Saksena N.K.; Salemi M.; and Vandamme A.M. Tracing the origin and history of the HIV-2 epidemic Proc. Natl Acad. Sci. USA 100 2003 6588 6592 (Pubitemid 36666625)
38. Pepin J.; Plamondon M.; Alves A.C.; Beaudet M.; and Labbe A.C. Parenteral transmission during excision and treatment of tuberculosis and trypanosomiasis may be responsible for the HIV-2 epidemic in Guinea-Bissau AIDS 20 2006 1303 1311 (Pubitemid 44030380)
39. + T lymphocytes J. Immunol. 178 2007 2862 2871 (Pubitemid 46333164)
40. Gilbert C.; Cantin R.; Barat C.; and Tremblay M.J. Human immunodeficiency virus type 1 replication in dendritic cell-T-cell cocultures is increased upon incorporation of host LFA-1 due to higher levels of virus production in immature dendritic cells J. Virol. 81 2007 7672 7682 (Pubitemid 47047852)
41. Garg R.; Lodge R.; Descoteaux A.; and Tremblay M.J. Leishmania infantum promastigotes reduce entry of HIV-1 into macrophages through a lipophosphoglycan-mediated disruption of lipid rafts J. Infect. Dis. 197 2008 1701 1708 (Pubitemid 351919634)
42. Stopak K.; de Noronha C.; Yonemoto W.; and Greene W.C. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability Mol. Cell 12 2003 591 601 (Pubitemid 37222482)
43. Cantin R.; Fortin J.F.; Lamontagne G.; and Tremblay M. The presence of host-derived HLA-DR1 on human immunodeficiency virus type 1 increases viral infectivity J. Virol. 71 1997 1922 1930 (Pubitemid 27078570)
44. Dornadula G.; Zhang H.; Shetty S.; and Pomerantz R.J. HIV-1 virions produced from replicating peripheral blood lymphocytes are more infectious than those from nonproliferating macrophages due to higher levels of intravirion reverse transcripts: implications for pathogenesis and transmission Virology 253 1999 10 16 (Pubitemid 29391554)
45. Clapham P.R.; McKnight A.; and Weiss R.A. Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines: induction and enhancement by soluble CD4 J. Virol. 66 1992 3531 3537
46. Bounou S.; Leclerc J.E.; and Tremblay M.J. Presence of host ICAM-1 in laboratory and clinical strains of human immunodeficiency virus type 1 increases virus infectivity and CD4(+)-T-cell depletion in human lymphoid tissue, a major site of replication in vivo J. Virol. 76 2002 1004 1014 (Pubitemid 34066404)
47. Suzuki Y.; Misawa N.; Sato C.; Ebina H.; Masuda T.; Yamamoto N.; and Koyanagi Y. Quantitative analysis of human immunodeficiency virus type 1 DNA dynamics by real-time PCR: integration efficiency in stimulated and unstimulated peripheral blood mononuclear cells Virus Genes 27 2003 177 188 (Pubitemid 37255568)
48. Zack J.A.; Arrigo S.J.; Weitsman S.R.; Go A.S.; Haislip A.; and Chen I.S. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure Cell 61 1990 213 222